Thursday October 23, 2014   
Find us Facebook Follow us on Twitter Watch us on YouTube    
Donate Now
  Search
  
CHARACTERIZING THE RESPONSE OF STEM AND PROGENITOR LIKE GLIOMA CELLS TO THE CHEMOTERHAPEUTIC AGENT TEMOZOLOMIDE by Lindy Barrett, PhD

CHARACTERIZING THE RESPONSE OF STEM AND PROGENITOR LIKE GLIOMA CELLS TO THE CHEMOTERHAPEUTIC AGENT TEMOZOLOMIDE

Led by Lindy Barrett, PhD at Memorial Sloan Kettering Cancer

High-grade gliomas are the most common primary brain tumors that develop in adults, and despite aggressive treatment strategies, including surgery, chemotherapy and radiotherapy, patients continue to have an extremely poor prognosis. One factor complicating the study and treatment of high-grade gliomas is the large number of diverse cell populations that make up an individual tumor. Some cell populations, including those that resemble stem cells, are thought to have greater contributions to glioma growth and resistance to therapeutic intervention. It is therefore critically important to obtain a more complete understanding of their biology. Both chemotherapy and radiotherapy can kill a subset of glioma cells, but they can also change the properties and behavior of cells that survive treatment, and contribute to tumor recurrence. The experiments in this research project will specifically focus how glioma cells, including stem cells, respond to the chemotherapeutic agent temozolomide (TMZ). This may inform on the optimization of therapeutic strategies that include TMZ, or on cell populations that play critical
roles within recurrent tumors.

Click here to view all of the grants VABC has funded

 

 
Voices Against Brain Cancer is a not-for-profit public charity recognized by the IRS under 501 (c) (3)